Upadacitinib for previously treated moderately to severely active Crohn’s disease
1.1 Upadacitinib is recommended as an option for treating moderately to severely active Crohn's disease in adults, only if:
• the disease has not responded well enough or lost response to a previous biological treatment or
• a previous biological treatment was not tolerated or
• tumour necrosis factor (TNF)-alpha inhibitors are contraindicated.
Upadacitinib is only recommended if the company provides it according to the commercial arrangement.